Structured evidence table for Omega-3 Cardiovascular Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Omega-3 Cardiovascular Randomized Trial | Neutral findings likely reflect moderate-dose combined EPA + DHA use, limited subgroup reporting on metabolic comorbidities (e.g., diabetes, hypertriglyceridemia) or concomitant therapies (e.g., statins), and high background guideline-directed medical therapy reducing residual risk. | 1 | Shayan SK (2026) | Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk. |
| Omega-3 Cardiovascular Randomized Trial | Although omega-3 fatty acids exert anti-inflammatory, antithrombotic, and lipid-modulating effects, this analysis indicates no broad benefit in reducing MACE or AF risk with combined moderate-dose EPA + DHA in heterogeneous post-event populations. | 1 | Shayan SK (2026) | Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk. |
| Omega-3 Cardiovascular Randomized Trial | Recent evidence highlights more MACE reductions with high-dose purified EPA monotherapy in high-metabolic-risk subgroups, balanced against dose-dependent AF increases at high doses (> 1.5 g/day). | 1 | Shayan SK (2026) | Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk. |
| Omega-3 Cardiovascular Randomized Trial | Cardiovascular diseases (CVD) remain to impose a main global burden of morbidity and mortality despite advances in anticipation and treatment. | 1 | Shayan SK (2026) | Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk. |
| Omega-3 Cardiovascular Randomized Trial | Most prior omega-3 outcome trials enrolled patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, but none specifically targeted patients receiving dialysis. | 3 | Mazón-Ruiz Jaime (2026) | Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurement |
| Omega-3 Cardiovascular Randomized Trial | REDUCE-IT demonstrated that cardiovascular risk reduction with EPA was consistent in patients with triglyceride levels above and below 150 mg/dl [], supporting mechanisms such as anti-inflammatory activity, membrane stabilization, and modulation of arrhythmic risk. | 3 | Mazón-Ruiz Jaime (2026) | Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurement |
| Omega-3 Cardiovascular Randomized Trial | In REDUCE-IT, the mineral-oil placebo was associated with modest increases in low-density lipoprotein cholesterol, apoB, and inflammatory biomarkers [,], raising concerns that part of the observed treatment effect could reflect comparator-related harm rather than pure benefit. | 3 | Mazón-Ruiz Jaime (2026) | Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurement |
| Omega-3 Cardiovascular Randomized Trial | New England Journal of Medicine 1 2 For more than two decades, large, randomized trials have repeatedly failed to demonstrate a clear cardiovascular benefit of therapies in patients receiving maintenance hemodialysis. | 3 | Mazón-Ruiz Jaime (2026) | Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurement |
Source documents